Absorption of enprofylline from the gastrointestinal tract in healthy subjects
- 1 January 1984
- journal article
- research article
- Published by Springer Nature in European Journal of Clinical Pharmacology
- Vol. 27 (3) , 329-333
- https://doi.org/10.1007/bf00542170
Abstract
Enprofylline, a new potent bronchodilator xanthine drug, was given orally as an aqueous solution to 6 healthy subjects in single doses of 2, 4 and 6 mg/kg. The two lower doses produced plasma concentrations in the range 1–4 mg/l, i.e. in the assumed “therapeutic interval” according to previous animal studies. A high 24 h urine recovery of unchanged drug, with mean values for the three dose levels ranging from 85 to 91% of the given dose, indicated good absorption and little metabolism. The dose-corrected area under the plasma concentration-time curve rose with dose as the latter was increased from 2 to 6 mg/kg. This indicates that the elimination of enprofylline is capacity-limited at high doses. Double peaks in the plasma concentration-time curves at the higher dose levels suggested intermittent and delayed gastric emptying as a possible explanation. This hypothesis was confirmed by studies in 6 other healthy subjects, who received the drug solution by three different routes; by mouth, via a catheter in the duodenum, and rectally via a catheter in the colon. The corresponding time to peak values (mean±SEM) were 32.5±8.7, 13.3±2.5, and 157±23 min.Keywords
This publication has 13 references indexed in Scilit:
- Tolerance and some Circulatory Effects of Intravenous and Oral Enprofylline in Healthy VolunteersActa Pharmacologica et Toxicologica, 2009
- INTRAVENOUS ENPROFYLLINE IN ASTHMA PATIENTS1984
- Enprofylline kinetics in healthy subjects after single dosesClinical Pharmacology & Therapeutics, 1983
- Intravenous administration of enprofylline to asthmatic patientsEuropean Journal of Clinical Pharmacology, 1983
- Enprofylline - Effects of a New Bronchodilating Xanthine Derivative in Asthmatic PatientsAllergy, 1983
- Tracheal relaxant and cardiostimulant actions of xanthines can be differentiated from diuretic and CNS-stimulant effects. Role of adenosine antagonism?Life Sciences, 1982
- Differentiation between bronchodilation and universal adenosine antagonism among xanthine derivativesLife Sciences, 1982
- Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung diseaseEuropean Journal of Clinical Pharmacology, 1982
- Enprofylline, a Principally New Antiasthmatic XanthineActa Pharmacologica et Toxicologica, 1981
- Theory of the mean absorption time, an adjunct to conventional bioavailability studiesJournal of Pharmacy and Pharmacology, 1978